

Jacobsen Stein
Form 4
November 16, 2010

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Jacobsen Stein

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [RMD]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

RESMED INC., 9001 SPECTRUM CENTER BLVD.

3. Date of Earliest Transaction (Month/Day/Year)
11/12/2010

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
COO, Europe

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

SAN DIEGO, CA 92123

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
| | | | Code | V | Amount | (D) | Price |
| ResMed Common Stock | 11/12/2010 | | M | | 24,000 | A | \$ 23.095 64,222.656 |
| ResMed Common Stock | 11/12/2010 | | S | | 24,000 | D | \$ 33.2538 40,222.656 (2) |
| ResMed Common Stock | 11/12/2010 | | M | | 37,500 | A | \$ 21.71 77,722.656 |
| ResMed Common | 11/12/2010 | | S | | 37,500 | D | \$ 33.214 40,222.656 (3) |

Edgar Filing: Jacobsen Stein - Form 4

| | | | | | | | | |
|---------------------------|------------|--|---|--------|---|-------------------------|------------|---|
| Stock | | | | | | | | |
| ResMed Common Stock | 11/12/2010 | | M | 6,000 | A | \$ 21.025 | 46,222.656 | D |
| ResMed Common Stock | 11/12/2010 | | S | 6,000 | D | \$ 33.25 | 40,222.656 | D |
| ResMed Common Stock | 11/12/2010 | | M | 10,000 | A | \$ 21.675 | 50,222.656 | D |
| ResMed Common Stock | 11/12/2010 | | S | 10,000 | D | \$ 33.25 | 40,222.656 | D |
| ResMed Common Stock | 11/12/2010 | | S | 10,222 | D | \$ 33.241 <u>(4)</u> | 30,000.656 | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|
| | | | | Code | V (A) (D) | Date Exercisable Expiration Date | Title Amount or Number of Shares |
| ResMed Common Stock Options | \$ 23.095 | 11/12/2010 | | M | 24,000 | 11/10/2007 ⁽¹⁾ 11/10/2013 | ResMed Common Stock 24,000 |
| ResMed Common Stock Options | \$ 21.71 | 11/12/2010 | | M | 37,500 | 08/01/2008 ⁽¹⁾ 08/01/2014 | ResMed Common Stock 37,500 |
| ResMed Common Stock | \$ 21.025 | 11/12/2010 | | M | 6,000 | 11/07/2008 ⁽¹⁾ 11/07/2014 | ResMed Common 6,000 |

| | | | | | | | | | |
|---------|-----------|------------|--|---|--------|---------------------------|------------|--------|--------|
| Stock | | | | | | | | | Stock |
| Options | | | | | | | | | |
| ResMed | | | | | | | | | ResMed |
| Common | \$ 21.675 | 11/12/2010 | | M | 10,000 | 10/01/2009 ⁽¹⁾ | 10/01/2015 | Common | 10,000 |
| Stock | | | | | | | | Stock | |
| Options | | | | | | | | | |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|----------------|-------|
| | Director | 10% Owner | Officer | Other |
| Jacobsen Stein RESMED INC. 9001 SPECTRUM CENTER BLVD. SAN DIEGO, CA 92123 | | | COO, Europe | |

Signatures

Stein Jacobsen 11/16/2010

**Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Disposition to issuer for tax withholding upon vesting of performance-based Restricted Stock Units granted on 12/17/2009 and vesting 11/11/2010.

(2) This transaction was executed in multiple trades at prices ranging from \$33.24 to 33.285. The price reported reflects the weighted average sale price. The reporting person will provide full information regarding the number of shares and prices at which the transaction was effected upon request to the SEC staff, the issuer or the security holder of the issuer.

(3) This transaction was executed in multiple trades at prices ranging from \$33.19 to 33.258. The price reported reflects the weighted average sale price. The reporting person will provide full information regarding the number of shares and prices at which the transaction was effected upon request to the SEC staff, the issuer or the security holder of the issuer.

(4) This transaction was executed in multiple trades at prices ranging from \$33.24 to 33.25. The price reported reflects the weighted average sale price. The reporting person will provide full information regarding the number of shares and prices at which the transaction was effected upon request to the SEC staff, the issuer or the security holder of the issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.